n-3 Polyunsaturated fatty acids supplementation in peripheral artery disease: the OMEGA-PAD trial.
Despite current consensus guidelines recommending intensive cardiovascular risk factor management for peripheral artery disease (PAD), patients suffering from PAD continue to experience significant morbidity and mortality. This excess morbid burden is at least partially related to impaired vascular function and systemic inflammation. Interventions bridging this gap are critical. Dietary supplementation of n-3 polyunsaturated fatty acids (n-3 PUFA) has been shown to improve endothelial function and reduce inflammation in different cohorts, as well as to decrease cardiovascular events in secondary prevention trials in patients with coronary artery disease. Their effects in the PAD population are, however, less well understood. The OMEGA-PAD trial is a double-blinded, randomized, placebo-controlled trial that examines the impact of a high-dose, short-duration dietary oral supplementation of n-3 PUFA on vascular function and inflammation in patients with established PAD. The purpose of this article is to provide a detailed description of the design and methods of the OMEGA-PAD trial, and a summary of baseline characteristics of the cohort.
Department of Surgery, University of California, San Francisco, San Francisco, CA, USA.
S Marlene
SM
Grenon
Christopher D
CD
Owens
Hugh
H
Alley
Karen
K
Chong
Priscilla K
PK
Yen
William
W
Harris
Millie
M
Hughes-Fulford
Michael S
MS
Conte
D000368:Aged; D002985:Clinical Protocols; D015331:Cohort Studies; D019587:Dietary Supplements; D004311:Double-Blind Method; D004730:Endothelium, Vascular / Q000503:physiopathology; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D058729:Peripheral Arterial Disease / Q000178:diet therapy* / Q000503:physiopathology
D015525:Fatty Acids, Omega-3
fatty acids; peripheral artery disease; randomized controlled trials